3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Meningioma
7
Brain Neoplasms
6
Leukemia, Myeloid, Acute
5
Head and Neck Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
3
Glioblastoma
3
Stomach Neoplasms
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia
2
Laryngeal Neoplasms
2
Gliosarcoma
2
Esophageal Neoplasms
2
Central Nervous System Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thrombocytosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pharyngeal Neoplasms
1
Paranasal Sinus Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Nose Neoplasms
1
Nasopharyngeal Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Interventions
Cyclophosphamide
192
Methotrexate
106
Cytarabine
86
fludarabine phosphate
80
Busulfan
71
Tacrolimus
70
Peripheral Blood Stem Cell Transplantation
69
Mycophenolic Acid
69
Whole-Body Irradiation
68
Vincristine
67
fludarabine
61
Filgrastim
61
Etoposide
59
Dexamethasone
54
Melphalan
52
Radiotherapy
47
Rituximab
46
Cyclosporine
46
Doxorubicin
38
Antilymphocyte Serum
37
Thiotepa
35
Granulocyte Colony-Stimulating Factor
35
Prednisone
34
Mercaptopurine
34
blinatumomab
33
pegaspargase
27
Methylprednisolone
27
Daunorubicin
26
Clofarabine
26
Asparaginase
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Hydroxyurea
×
Clear all
NCT03860844
2025-09-09
ISAKIDS
Sanofi
Phase 2
Terminated
67 enrolled
25 charts